CEO: Damià Tormo

Advent Contact: Raj Parekh

First-in-class therapy for autoimmune disease

Artax is discovering small molecules that target Nck, a key cytoplasmic adapter protein, recently discovered to play a key role in T-cell signalling and activation. The Artax approach has the potential to reduce auto-immunity without affecting the ability of the immune system to respond to an infectious challenge.

Advent invested in the Series B in 2015.


Artax Biopharma Funded to Clinically Develop Breakthrough Oral Therapies for Autoimmune Diseases